Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to 369.44%.

  • Gossamer Bio's EBIT Margin fell 116500.0% to 369.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 802.08%, marking a year-over-year decrease of 7329400.0%. This contributed to the annual value of 66.06% for FY2024, which is N/A changed from last year.
  • Per Gossamer Bio's latest filing, its EBIT Margin stood at 369.44% for Q3 2025, which was down 116500.0% from 337.41% recorded in Q2 2025.
  • Gossamer Bio's 5-year EBIT Margin high stood at 1612.12% for Q3 2022, and its period low was 372.23% during Q1 2025.
  • For the 4-year period, Gossamer Bio's EBIT Margin averaged around 593.99%, with its median value being 247.08% (2024).
  • Over the last 5 years, Gossamer Bio's EBIT Margin had its largest YoY gain of -116500bps in 2025, and its largest YoY loss of -3917600bps in 2025.
  • Quarter analysis of 4 years shows Gossamer Bio's EBIT Margin stood at 1572.37% in 2022, then dropped by -13bps to 1369.77% in 2023, then crashed by -82bps to 247.08% in 2024, then crashed by -250bps to 369.44% in 2025.
  • Its EBIT Margin stands at 369.44% for Q3 2025, versus 337.41% for Q2 2025 and 372.23% for Q1 2025.